248 related articles for article (PubMed ID: 27149266)
1. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants.
Li RC; Huang T; Li Y; Wang LH; Tao J; Fu B; Si G; Nong Y; Mo Z; Liao X; Luan I; Tang H; Rathi N; Karkada N; Han HH
Hum Vaccin Immunother; 2016 Mar; 12(3):785-93. PubMed ID: 27149266
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe.
Vesikari T; Karvonen A; Prymula R; Schuster V; Tejedor JC; Thollot F; Garcia-Corbeira P; Damaso S; Han HH; Bouckenooghe A
Vaccine; 2010 Jul; 28(32):5272-9. PubMed ID: 20538094
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007.
Anh DD; Carlos CC; Thiem DV; Hutagalung Y; Gatchalian S; Bock HL; Smolenov I; Suryakiran PV; Han HH
Vaccine; 2011 Mar; 29(11):2029-36. PubMed ID: 21256876
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.
Steele AD; Reynders J; Scholtz F; Bos P; de Beer MC; Tumbo J; Van der Merwe CF; Delem A; De Vos B
J Infect Dis; 2010 Sep; 202 Suppl():S93-100. PubMed ID: 20684724
[TBL] [Abstract][Full Text] [Related]
5. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.
Li RC; Li YP; Mo ZJ; Luo D; Huang T; Kong JL; Wang LH; Song NS; Liu A; Zhang H; Liao X; Karkada N; Han HH
Hum Vaccin Immunother; 2013 Aug; 9(8):1638-42. PubMed ID: 23807360
[TBL] [Abstract][Full Text] [Related]
6. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines.
Steele AD; De Vos B; Tumbo J; Reynders J; Scholtz F; Bos P; de Beer MC; Van der Merwe CF; Delem A
Vaccine; 2010 Sep; 28(39):6542-8. PubMed ID: 18786585
[TBL] [Abstract][Full Text] [Related]
7. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
9. Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants.
Tanaka Y; Yokokawa R; Rong HS; Kishino H; Stek JE; Nelson M; Lawrence J
Hum Vaccin Immunother; 2017 Jun; 13(6):1-7. PubMed ID: 28140752
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study.
Kim JS; Bae CW; Lee KY; Park MS; Choi YY; Kim KN; Kim JD; Park WS; Sin JB; Kim EA; Lee SG; Kim CS; Cha SH; Hong YJ; Shin SM; Shim GH; Choi KM; Yang JW; Liu A; Suryakiran PV; Han HH
Hum Vaccin Immunother; 2012 Jun; 8(6):806-12. PubMed ID: 22699440
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants.
Narang A; Bose A; Pandit AN; Dutta P; Kang G; Bhattacharya SK; Datta SK; Suryakiran PV; Delem A; Han HH; Bock HL
Hum Vaccin; 2009 Jun; 5(6):414-9. PubMed ID: 19276664
[TBL] [Abstract][Full Text] [Related]
12. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
13. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS
Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study.
Gillard P; Tamura T; Kuroki H; Morikawa Y; Moerman L; Parra J; Kitamura Y; Mihara K; Okamasa A
Hum Vaccin Immunother; 2019; 15(4):800-808. PubMed ID: 30785851
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.
Vesikari T; Karvonen A; Bouckenooghe A; Suryakiran PV; Smolenov I; Han HH
Vaccine; 2011 Mar; 29(11):2079-84. PubMed ID: 21238572
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 °C for seven days.
Kerdpanich A; Chokephaibulkit K; Watanaveeradej V; Vanprapar N; Simasathien S; Phavichitr N; Bock HL; Damaso S; Hutagalung Y; Han HH
Hum Vaccin; 2011 Jan; 7(1):74-80. PubMed ID: 21228629
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.
Salinas B; Pérez Schael I; Linhares AC; Ruiz Palacios GM; Guerrero ML; Yarzábal JP; Cervantes Y; Costa Clemens S; Damaso S; Hardt K; De Vos B
Pediatr Infect Dis J; 2005 Sep; 24(9):807-16. PubMed ID: 16148848
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
20. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age.
Zaman K; Sack DA; Yunus M; Arifeen SE; Podder G; Azim T; Luby S; Breiman RF; Neuzil K; Datta SK; Delem A; Suryakiran PV; Bock HL;
Vaccine; 2009 Feb; 27(9):1333-9. PubMed ID: 19162114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
